NexImmune, Inc. (NEXI)

USD 0.23

(0.0%)

Market Cap (In USD)

323.56 Thousand

Revenue (In USD)

-

Net Income (In USD)

-32.34 Million

Avg. Volume

609.2 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.2-28.695
PE
-
EPS
-
Beta Value
1.692
ISIN
US65344D2080
CUSIP
65344D109
CIK
1538210
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Trainer M.B.A.
Employee Count
-
Website
https://www.neximmune.com
Ipo Date
2021-02-12
Details
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.